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Introduction: Understanding the mechanism of stem cell mobilization into injured skeletal muscles is a prerequisite
step for the development of muscle disease therapies. Many of the currently studied stem cell types present myogenic
potential; however, when introduced either into the blood stream or directly into the tissue, they are not able to
efficiently engraft injured muscle. For this reason their use in therapy is still limited. Previously, we have shown
that stromal-derived factor-1 (Sdf-1) caused the mobilization of endogenous (not transplanted) stem cells into
injured skeletal muscle improving regeneration. Here, we demonstrate that the beneficial effect of Sdf-1 relies on
the upregulation of the tetraspanin CD9 expression in stem cells.
Methods: The expression pattern of adhesion proteins, including CD9, was analysed after Sdf-1 treatment during
regeneration of rat skeletal muscles and mouse Pax7-/- skeletal muscles, that are characterized by the decreased
number of satellite cells. Next, we examined the changes in CD9 level in satellite cells-derived myoblasts, bone
marrow-derived mesenchymal stem cells, and embryonic stem cells after Sdf-1 treatment or silencing expression
of CXCR4 and CXCR7. Finally, we examined the potential of stem cells to fuse with myoblasts after Sdf-1 treatment.
Results: In vivo analyses of Pax7-/- mice strongly suggest that Sdf-1-mediates increase in CD9 levels also in mobilized
stem cells. In the absence of CXCR4 receptor the effect of Sdf-1 on CD9 expression is blocked. Next, in vitro studies
show that Sdf-1 increases the level of CD9 not only in satellite cell-derived myoblasts but also in bone marrow derived
mesenchymal stem cells, as well as embryonic stem cells. Importantly, the Sdf-1 treated cells migrate and fuse with
myoblasts more effectively.
Conclusions: We suggest that Sdf-1 binding CXCR4 receptor improves skeletal muscle regeneration by upregulating
expression of CD9 and thus, impacting at stem cells mobilization to the injured muscles.Introduction
Skeletal muscle regeneration is a complex process of tis-
sue degeneration and reconstruction [1]. The process
mostly relies on the presence of muscle-specific uni-
potent stem cells; that is, satellite cells. However, the
myogenic potential has also been shown for other popu-
lations of stem and progenitor cells [2]. Quiescent satel-
lite cells that express transcription factor Pax7 are
located between myofiber sarcolemma and basal lamina.
In the response to muscle injury these cells are activated,
begin to proliferate, differentiate into myoblasts, and
fuse to form multinucleated myotubes and then muscle* Correspondence: edbrzoska@biol.uw.edu.pl
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unless otherwise stated.fibres. Satellite cell-derived myoblasts start to express
myogenic regulatory factors responsible for their proper
differentiation, such as Myod1, Myf5, Myf6, and myo-
genin [3]. The satellite cells, being muscle-specific stem
cells, appear to be the cells of first choice to be tested in
muscle therapies [4]. Nevertheless, for many reasons,
their use is still limited. Among the major obstacles pre-
venting the application of satellite cell-derived myoblasts
in therapy, one can include their restricted ability to mi-
grate through the vasculature to effectively engraft in-
jured muscle, their rapid cell death after transplantation,
and their limited regenerative capacity after in vitro cul-
ture [5].
Skeletal muscles serve as a niche not only for satellite
cells but also for a few other populations of stem cells.
These include muscle side population cells that were. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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33342 dye from their cytoplasm as well as the presence
of stem cell antigen Sca1 and CD45 proteins [6]. In 2002
Asakura and Rudnicki demonstrated that these cells
could fuse with myoblasts in vitro and also contribute to
the formation of 1% of new myofibres when transplanted
into the damaged anterior tibialis muscle of SCID mice
[7]. Next, a small population (0.25%) of muscle side
population-expressing satellite cell markers (that is, Pax7
and syndecan-4) as well as side population markers (that
is, ATP-binding cassette subfamily member ABCG2
transport protein and stem cell antigen Sca1) partici-
pated in the formation of 30% of muscle fibres when
transplanted into a damaged mouse anterior tibialis
muscle and as many as 70% of the myofibres when
transplanted into the anterior tibialis muscle of mdx
mice [8]. Other populations of stem cells present within
the skeletal muscle are pericytes associated with small
blood vessels [9], mesangioblasts [10-13], AC133 stem
cells that express CD133 [14], as well as PW1+/Pax7–
interstitial cells that synthesise PW1/PEG3 protein
involved in tumour necrosis factor alpha–nuclear factor-
κB signalling and do not express Pax7 protein [15].
These cells could undergo myogenic differentiation
in vitro and in vivo; that is, after transplantation into re-
generating mouse muscles. Furthermore, various tissues,
including skeletal muscle, house multipotential mesen-
chymal stem cells (MSCs) that are defined based on ad-
hesion to plastic, fibroblast-like morphology, intensive
proliferation in vitro, and the ability to differentiate into
adipocytes, chondrocytes, osteoblasts, and skeletal myo-
blasts [16,17]. MSCs isolated from mouse bone marrow
improved muscle regeneration and also reduced fibrosis;
that is, excessive development of connective tissue [18].
Moreover, MSCs isolated from the synovial membrane
participated in the regeneration of mouse skeletal mus-
cles and were present in the satellite cell niche. These
cells also partially improved the function of skeletal
muscle of mdx mice [17]. Additionally, many experi-
ments showed that the regeneration of skeletal muscle
can also be supported by stem cells isolated from tissues
other than skeletal muscle. Among these were stem cells
derived from bone marrow [19], human umbilical cord
blood [20,21], human umbilical cord Wharton’s jelly
[22], and hematopoietic stem cells [23]. Furthermore,
pluripotent stem cells such as embryonic stem cells
(ESCs) [24,25] or induced pluripotent stem cells [26-28]
could also follow a myogenic programme.
Even if many of the stem or progenitor cells manifest
myogenic potential, they are rarely readily available for
transplantation into injured muscle. First, transplant-
ation of exogenous stem cells can be only effective when
high doses of cells, ranging from 25 × 106/cm2 to 67.5 ×
106/cm2 cells, could be administered directly into themuscle (100 injections per 1 cm2) [29]. Second, trans-
planted cells are rarely able to migrate within injured
muscle and for this reason they usually remain only at
the site of the injection. Next, the method of cell admin-
istration can be also an issue. Despite their myogenic po-
tential, many of the stem cells tested were not able to
engraft injured muscle when transplanted into the
bloodstream. This makes their use in therapy rather dif-
ficult and limited. Presently, the major limitations that
contribute to the failure of clinical trials are caused by
the lack of specific methods supporting homing of the
stem cells after their systemic infusion. Summarising,
comprehensive in vitro and in vivo studies demonstrated
that many of stem cell populations are characterised by
myogenic potential; that is, the ability to differentiate
into myoblasts and muscle fibres and also to colonise
the satellite cell niche. Next, the transplantation of these
cells could improve regeneration of damaged muscles.
However, their physiological role in the reconstruction
of skeletal muscle remains unexplained.
In our previous study we showed that stromal-derived
factor-1 (Sdf-1, also known as CXCL12) treatment im-
proved skeletal muscle regeneration by enhancing en-
dogenous (not transplanted) stem cell mobilisation into
injured muscle [30]. Sdf-1 belongs to the cytokine family
and acts on the cells expressing receptor CXC chemo-
kine receptor (CXCR)-4 and/or CXCR7 [31]. Moreover,
we were also analysing the role of various adhesion pro-
teins in myoblast differentiation. M-cadherin [32], adhe-
sion protein complex composed of ADAM-12, CD9,
CD81, integrin beta1, and alpha3 [33], as well as
syndecan-4 were shown by us to be engaged in myoblast
differentiation [34]. Next, crucial function in this process
of such proteins as integrin alpha7 [35], alpha9 [36], and
other adhesion proteins was shown by other studies.
In the current study, we documented how Sdf-1 im-
pacts on myoblasts and other stem cell properties, im-
proving their ability to participate in the skeletal muscle
regeneration. We also show that preconditioning of stem
cells with Sdf-1 could be an effective approach to opti-
mise stem cell migration and engraftment to injured
muscles. Our results thus underline the mechanism that
could be activated in order to mobilise endogenous cells
into injured tissue. Importantly, this mechanism could
also be switched on in order to enhance homing of the
transplanted cells to the target tissues, and thus could
allow reduction of the number of cells needed for the
therapy.Materials and methods
All procedures involving animals were approved by
First Warsaw Local Ethics Committee for Animal
Experimentation.
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Rat satellite cell-derived myoblasts
Slow twitch soleus muscles were dissected from the hind
limbs of 3-month-old male WAG rats. The satellite cells
were isolated by muscle digestion with 0.15% pronase
(Sigma-Aldrich, St. Louis, MO, United States) in HAM’s F-
12 medium (Life Technologies, Carlsbad, California, United
States) buffered with 10 mM HEPES (Sigma-Aldrich) sup-
plemented with 10% foetal bovine serum (FBS; Life Tech-
nologies). Cells were plated on 2% gelatine-coated (Sigma-
Aldrich) dishes in complete Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies) supplemented with
10% FBS, 10% horse serum (Life Technologies), and 1% anti-
biotics (AB, 50 U/ml penicillin, 50 μg/ml streptomycin; Life
Technologies). Cells were cultured at 37°C in an atmosphere
of 5% carbon dioxide. The medium was changed every
2 days. Starting from day 3 of culture, cells were treated with
100 ng/ml Sdf-1. The control cells were cultured in the ab-
sence of Sdf-1 in the medium. The cells were subjected ei-
ther to quantitative RT-PCR, immunolocalisation, or western
blotting. The morphology of cells was analysed using a
Nikon Eclipse TE200 microscope (Nikon Instruments,
Tokyo, Japan) with Hoffman contrast.
C2C12 myoblasts
Mouse C2C12 myoblasts (obtained from the European Col-
lection of Cell Cultures, Porton Down, United Kingdom)
were plated in DMEM supplemented with 10% FBS and 1%
AB, on 2% gelatine-coated plates. Cells were cultured at 37°C
in an atmosphere of 5% carbon dioxide. The morphology of
cells was analysed using a Nikon Eclipse TE200 microscope
with Hoffman contrast. The cells were subjected either to
Sdf-1 treatment, transfection with small interfering RNA
(siRNA) complementary to mRNA encoding CXCR4, quan-
titative RT-PCR, or immunolocalisation or used for co-
culture experiments.
Mouse bone marrow-derived mesenchymal stem cells
The bones were dissected from the hind limbs of 3-month-
old male C57Bl6N mice carrying the lacZ transgene in the
ROSA26 locus. Next, the ends of the bones were cut and
bone marrow was washed out with saline using a 22 G nee-
dle. Obtained cells were washed twice with saline. Erythro-
cytes were then removed by gradient centrifugation in
Histopaque (Sigma-Aldrich) for 20 minutes at 1,800 rpm.
Obtained mononucleate cells were separated using a mag-
netic column (MACS; Miltenyl Biotec, Bergisch Gladbach,
Germany) with anti-CXCR4 specific antibody (Abcam, Cam-
bridge, United Kingdom), according to the manufacturer’s in-
struction. The CXCR4+ fraction of cells was cultured in α-
minimum essential medium (Sigma-Aldrich) supplemented
with 20% FBS, 200 mML-glutamine (Life Technologies), and
1% AB. The morphology of cells was analysed using a Nikon
Eclipse TE200 microscope with Hoffman contrast. Thecells were subjected either to Sdf-1 treatment, quantitative
RT-PCR, or immunolocalisation or used for co-culture
experiments.
Mouse embryonic stem cells
ESCs constitutively expressing histone H2B-GFP were pro-
vided by Dr Kat Hadjantonakis [37]. Mitomycin-inactivated
mouse embryonic fibroblasts, which served as the feeder
layer for ESCs, were plated on dishes coated with 1% gel-
atine (Sigma-Aldrich) in DMEM supplemented with 10%
FBS and 1% AB. Twenty-four hours later ESCs were seeded
onto the inactivated mouse embryonic fibroblasts and cul-
tured in knockout DMEM (Life Technologies) supple-
mented with 15% ES-qualified FBS (Life Technologies),
0.1 mM nonessential amino acids (Sigma-Aldrich),
200 mML-glutamine (Life Technologies), 0.1 mM β-
mercaptoethanol (Sigma-Aldrich), 1% AB, and 500 U/ml
leukaemia inhibitory factor (Chemicon, Billerica, MA,
United States). Prior to transfection, ESCs were separated
from mouse embryonic fibroblasts by the preplating tech-
nique and cultured on dishes coated with Matrigel Matrix
Growth Factor Reduced (1 mg/ml DMEM; BD Biosciences,
Becton-Dickinson, San Jose, CA, United States). The
morphology of cells was analysed using a Nikon Eclipse
TE200 microscope with Hoffman contrast. The cells were
subjected either to Sdf-1 treatment, transfection with
siRNA complementary to mRNA encoding CXCR4 or
CXCR7, quantitative RT-PCR, immunolocalisation, or west-
ern blotting or used for co-culture experiments.
Sdf-1 treatment and silencing of CXCR4 or CXCR7
expression by RNA interference
C2C12 or ESCs were plated on plates covered with
Matrigel Matrix Growth Factor Reduced (BD Biosci-
ences). After reaching 30 to 40% confluence the cells
were transfected with Silencer Select Pre-designed
siRNA (Life Technologies) complementary to mRNAs
encoding either CXCR4 9 (ID:s64091) or CXCR7
(ID:s64124). Appropriate, recommended negative con-
trol siRNA was used. siRNA duplexes were diluted in
DMEM to reach the concentration of 100 pmol per plate
and incubated with Lipofectamine RNAiMAX (Life
Technologies), according to the manufacturer’s instruc-
tions. After 24 hours the cells were treated with Sdf-1
(10 ng/μl). Next, cells were collected 48 hours post Sdf-1
treatment and processed either for mRNA isolation
followed by quantitative RT-PCR, immunolocalisation,
or western blotting. The efficiency of CXCR4 or CXCR7
downregulation was tested by quantitative RT-PCR and
immunocytochemistry.
Co-culture of stem cells and mouse C2C12 myoblasts
C2C12 myoblasts were plated at density of 3 × 104 in
DMEM with 10% FBS and 1% AB. When C2C12 cells
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derived mesenchymal stem cells (BM-MSCs) or ESCs –
control or pretreated with Sdf-1 – were seeded. Respect-
ively, 5 × 106 ESCs and 2 × 104 BM-MSCs were added.
After 24 hours the medium was changed for differentiation;
that is, DMEM supplemented with 3% horse serum and 1%
AB. After 14 days of co-culture, cells were fixed in 3% para-
formaldehyde (Sigma-Aldrich) and then processed for
immunolocalisation of selected antigens, as described
below. Skeletal myosin heavy and light chains (Sigma-Al-
drich) were localised to define differentiated myotubes in
ESC and myoblast co-cultures. β-galactosidase (Abcam)
was localised to identified BM-MSCs in co-cultures with
myoblasts. Cell nuclei were visualised with DraQ5 (Biosta-
tus Limited, Biostatus Ltd, Leicestershire, United Kingdom)
diluted in PBS. Cultures were analysed using confocal
microscope Axiovert 100 M (Zeiss, Carl Zeiss Inc., Jena,
Germany) and LSM 510 application software (Carl Zeiss
Inc., Jena, Germany). The same image acquisition settings
were used for all comparisons. For each experimental
group, the number of hybrid myotubes was counted from
50 random fields of view. Data are the mean ± standard de-
viation of three biological replicates. Results were analysed
by Student’s t test using GraphPadPrism (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). Differences were considered
statistically significant when P <0.05.
Migration assay
BM-MSCs or ESCs were plated into the inserts of six-well
dishes (8 μm pores; BD Biosciences). Both inserts and wells
were coated with Matrigel Matrix Growth Factor Reduced.
After 24 hours of culture, the medium in the lower dish was
replaced with the medium supplemented with 50 ng/ml Sdf-
1. Control cells were cultured in medium lacking Sdf-1. After
48 hours of culture the cells were fixed and stained with
Giemsa (Merck, Merck KGaA, Darmstadt, Germany). The
number of cells that migrated from the inserts and localised
either at the membrane surface facing the lower dish or at
the bottom of the lower dish was counted. Three independ-
ent experiments were performed for each analysis. Data are
the mean ± standard deviation of three biological replicates.
Statistical analysis was performed with unpaired t test using
GraphPadPrism (GraphPad Software, Inc.). The results
were considered to be significantly different when P <0.05.
Muscle injury
The regeneration of slow twitch soleus skeletal muscles
was induced in 3-month-old male WAG rats. Briefly, the
animals were anaesthetised with pentobarbital sodium
salt (Sigma-Aldrich) by an intraperitoneal injection
(30 mg/kg body mass). Next, muscles were exposed, de-
nervated, and crushed as described previously [30]. Mus-
cles were injected with 100 ng Sdf-1 diluted in 20 μl
physiological saline. Two injections, 10 μl each, wereadministered into two different parts of muscle. The con-
trol muscles were injected with 20 μl physiological saline.
The animals were euthanised with carbon dioxide at days 1,
3, and 7 after the muscle injury. Next, injured muscles were
isolated, weighed, and collected for further analysis.
Quantitative RT-PCR
Total RNA was isolated from muscles, satellite cell-
derived myoblasts, and C2C12 myoblasts using the High
Pure Isolation Kit (Roche Applied Science, Penzberg,
Germany), according to the manufacturer’s protocol.
RNA was extracted from biological replicates (two C2C12
cultures or three primary cell cultures or three muscle
samples per each experimental time point). Then 100 ng
RNA from each sample was reverse-transcribed using the
RT2 First Strand Kit (SABiosciences, Qiagen, Valencia,
CA, United States) or the Transcriptor First Strand cDNA
Synthesis Kit (Roche Applied Science) according to the
manufacturer’s protocol, for muscles and myoblasts, re-
spectively. Next, mRNA levels in muscles and satellite
cell-derived myoblasts were examined using a custom
PCR array (SABiosciences) for the genes m-cadherin,
ADAM12, syndecan-4, CD9, CD81, integrin beta1 (itgb1),
alpha3 (itga3), alpha7 (itga7), and alpha9 (itga9) according
to the manufacturer’s protocol. mRNA levels in C2C12
myoblasts were examined using a custom PCR array based
on Universal ProbeLibrary (Roche Applied Science) for the
following genes: m-cadherin, ADAM12, CD9, CD81, itgb1,
itga3, itga7, and itga9. Hypoxanthine phosphoribosyltrans-
ferase 1 (Hprt1) [RefSeq:NM_012583], glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) [RefSeq:NM_017008],
beta-2-microglobulin (B2m) [RefSeq:NM_012512], and
acidic ribosomal phosphoprotein P1 (Rplp1) [RefSeq:NM_
001007604] were used as the candidate reference genes.
Quantitative real-time PCR analyses were performed with
the RT2 Real-Time PCR Master Mix (SABiosciences) in
the 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, United States) or with the LightCycler
480 Probes Master 9.0 (Roche Applied Sciences) in the
LightCycler 480 (Roche Applied Sciences), according to
the PCR array manufacturer’s instruction. Threshold
cycle (Ct) values of the analysed amplicons were deter-
mined with SDS 2.1 software (Applied Biosystems) or
LightCycler® 480 Software (Roche Applied Science). Ex-
pression levels were calculated with the 2–(ΔCT) formula
using DataAssist™ software (Applied Biosystems) or the
relative quantification tool in LightCycler® 480 Soft-
ware. The geNorm™ algorithm integrated into DataAs-
sist™ was used to evaluate the stability of the candidate
reference genes. The expression level and standard de-
viation for each gene was represented as the column
charts using GraphPadPrism. All the candidate refer-
ence genes (B2m, Gapdh, Hprt, and Rplp1) displayed
high expression stability, as determined by the
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malisation of the expression data. Data are the mean ±
standard deviation of two (C2C12) or three biological
replicates, each analysed in two technical replicates.
Results were analysed by ratio paired t test and differ-
ences were considered statistically significant when
P <0.05.
Analyses of mRNA levels in BM-MSCs and ESCs in-
cluded RNA isolation using the mirVana kit (Life Technolo-
gies) and then reverse transcription using Superscript (Life
Technologies). The TaqMan assays (Life Technologies) and
Master Mix (Life Technologies) were used to analyse the
level of the genes CXCR4, CXCR7, and CD9 according to
the PCR array manufacturer’s instructions. Hprt1 was used
as the reference gene. All reactions were performed in trip-
licates. The conditions of quantitative RT-PCR were as fol-
lows: reverse transcription, 25°C for 10 minutes, 42°C for
60 minutes, and 85°C for 5 minutes; quantitative PCR, tem-
plate denaturation, 95°C for 10 minutes, and 45 cycles of
95°C for 15 seconds and 60°C for 60 seconds. The collected
data were analysed using LightCycler 96SW 1.1 software
(Roche Applied Sciences). Data are the mean ± standard de-
viation of three biological replicates, each analysed in two
technical replicates. Results were analysed by paired t test
and differences were considered statistically significant
when P <0.05.
Immunocytochemistry
Selected antigens were immunolocalised in sections of re-
generating muscles, as well as in in vitro cultured cells.
Cells cultured were fixed with 3% paraformaldehyde for
10 minutes. Muscle cryosections were hydrated in PBS,
fixed in 3% paraformaldehyde and washed with PBS. Next,
sections or cells were permeabilised with 0.1% Triton
X-100/PBS (Sigma-Aldrich), and incubated with 0.25% gly-
cine (Sigma-Aldrich). Nonspecific binding of antibodies
was blocked with 3% bovine serum albumin (Sigma-Al-
drich) with 2% donkey serum (Sigma-Aldrich) for 1 hour.
Samples were then incubated with primary antibodies di-
luted 1:100 in 3% bovine serum albumin overnight,
washed with PBS, and incubated at room temperature
with secondary antibodies diluted 1:200 in 3% bovine
serum albumin for 1.5 hours. After washing with PBS,
cell nuclei were visualised by incubation with DraQ5
(Biostatus Limited) diluted 1:1,000 in PBS for 10 minutes.
Specimens were mounted with Fluorescent Mounting
Medium (Dako Cytomation, Glostrup, Denmark). After
the procedure was completed samples were analysed
using the confocal microscope Axiovert 100 M (Zeiss)
and LSM 510 software. The same image acquisition set-
tings were used for all comparisons. The following pri-
mary antibodies were used: rabbit polyclonal anti-skeletal
myosin (M7523; Sigma-Aldrich), rabbit polyclonal anti-
β-galactosidase (ab12081; Abcam), mouse monoclonalanti-integrin alpha3 (sc-7019; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit polyclonal anti-integrin beta1
(sc-9936; Santa Cruz), rabbit polyclonal anti-ADAM12
(ab39155; Abcam), rabbit polyclonal anti-CD9 (C9993;
Sigma-Aldrich), rabbit polyclonal anti-CXCR4 (ab2074;
Abcam), rabbit polyclonal anti-CXCR7 (ab117836; Abcam),
goat polyclonal anti-CD81 (sc-7102; Santa Cruz), mouse
monoclonal anti-M-cadherin (ab78090; Abcam), and rabbit
polyclonal anti-VCAM-1 (sc-8304; Santa Cruz). Secondary
antibodies directed against mouse or rabbit primary anti-
bodies conjugated with Alexa488, Alexa594, and Alexa633
were used (A21202, A11059, A21206, A11034, A11080,
A21203, A11037, A21071, A21082, A21063; Life Technolo-
gies). Appropriate controls of secondary antibodies were
performed.
Western blotting
Fifty micrograms of total protein lysate were denatured by
boiling in Laemmli buffer, separated using SDS-PAGE electro-
phoresis, and transferred to polyvinylidene fluoride mem-
branes (Roche Applied Science). The membranes were
washed, blocked with 5% Blotto (BioRad, Bio-Rad, Hercules,
CA, USA) and Tris-buffered saline for 1 hour, and incubated
at 4°C with primary antibodies diluted 1:2,000 in 5% Blotto
(BioRad) and Tris-buffered saline overnight, followed by sec-
ondary antibodies diluted 1:20,000 for 2 hours. Next, protein
bands were visualised with SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Fisher Scientific, Langenselbold,
Germany) and exposed to chemiluminescence positive film
(Amersham Hyperfilm ECL; GE Healthcare, Little Chalfont,
Buckinghamshire, United Kingdom). The obtained results
were analysed with GelDoc2000 using Quantity One software
(BioRad). Primary antibodies used were mouse monoclonal
anti-integrin alpha3 (sc-7019; Santa Cruz), rabbit polyclonal
anti-integrin beta1 (sc-9936; Santa Cruz), rabbit polyclonal
anti-ADAM12 (ab39155; Abcam), rabbit polyclonal anti-CD9
(C9993; Sigma-Aldrich), goat polyclonal anti-CD81 (sc-7102;
Santa Cruz), rabbit polyclonal anti-CXCR4 (ab2074; Abcam),
rabbit polyclonal anti-CXCR7 (ab117836; Abcam), rabbit poly-
clonal anti-M-cadherin (sc-10734; Santa Cruz), rabbit poly-
clonal anti-VCAM-1 (sc-8304; Santa Cruz), and mouse
monoclonal anti-tubulin (T5168; Sigma-Aldrich). Secondary
antibodies used were peroxidase-conjugate rabbit anti-mouse
(A9044; Sigma-Aldrich), peroxidase-conjugate rabbit anti-goat
(A5420; Sigma-Aldrich), and peroxidase-conjugate goat anti-
rabbit (A9169; Sigma-Aldrich). Three independent experi-
ments were performed.
Results
Sdf-1 treatment changes expression of adhesion proteins
during myoblast differentiation in vitro and in vivo in
regenerating muscle
In our previous studies we evidenced that Sdf-1 im-
proved muscle regeneration, stem cell mobilisation, and
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crucial role in the myogenic processes we decided to
focus on the possible link between Sdf-1 and those pro-
teins engaged in myoblast migration and differentiation.
To verify the existence of such a link we first focused on
skeletal muscle regeneration.
To follow the impact of Sdf-1 on regeneration, soleus
muscles of WAG rats were injected with Sdf-1 (100 ng
per muscle) after the muscle injury. Next, we analysed
nontreated (control) and Sdf-1-treated muscles at days 1
and 3 of regeneration (Figure 1). Activated satellite cells
start to proliferate (day 1), differentiate into myoblasts
(day 3) that fuse (day 7) to form myotubes, and recon-
struct damaged myofibres. The levels of mRNAs encod-
ing adhesion proteins (that is, i.e. m-cadherin, ADAM-
12, syndecan-4, CD9, CD81, integrin beta1, alpha3,
alpha7, and alpha9) were compared between control and
Sdf-1-treated muscles, at days 1 and 3 of regeneration.
At day 3, Sdf-1 significantly increased expression of m-
cadherin, ADAM-12, and integrin alpha9 at the mRNA
level (Figure 1A). Changes in mRNA levels was readily
translated to the levels of m-cadherin, ADAM-12, andFigure 1 Sdf-1 impact on the expression of adhesion proteins in rege
mRNAs encoding m-cadherin, ADAM-12, syndecan-4, CD9, CD81, integrin β
in control and Sdf-1-treated muscles (Sdf-1) at days 1 and 3 of regeneratio
control and Sdf-1-treated muscles at day 3 of regeneration. Bar = 50 μm. (C
day 7 of regeneration. (D) Level of m-cadherin, itga9, and CD9 protein dur
and 7 (C – intact muscle). *P <0.05. Error bars indicate standard deviation.integrin alpha9 proteins, which dramatically increased
in mononucleated cells present within the regenerat-
ing muscle (day 3), as shown by immunolocalisation
(Figure 1B). We did not observe significant changes in
the mRNAs encoding other analysed factors; that is,
syndecan-4, CD9, CD81, integrin beta1, alpha3, and
alpha7. However, immunolocalisation revealed that
Sdf-1 impacted one of the tetraspanins (that is, CD9).
Immunolocalisation of CD9 showed that this tetraspa-
nin was present in mononucleated cells both in con-
trol and Sdf-1-treated muscles at day 3 of regeneration
of the soleus muscle (Figure 1B). At day 7 of regener-
ation, CD9 was still detectable in mononucleated cells
and rarely in newly formed myofibres in control mus-
cles (Figure 1C). However, in Sdf-1-treated muscles
this protein was detectable in mononucleated cells
and significantly in the cell membranes of newly
formed myofibres (Figure 1C). Western blotting also
showed the changes at the protein level after Sdf-1
treatment (Figure 1D). The level of m-cadherin, itga9,
and CD9 increased at days 1 and 3 of muscle regener-
ation in response to Sdf-1 treatment. The changes innerating rat soleus muscle. (A) Quantitative RT-PCR analysis of
1 (itgb1), integrin α3 (itga3), integrin α7 (itga7), and integrin α9 (itga9)
n. (B) Immunolocalisation of m-cadherin, ADAM-12, itga9, and CD9 in
) Immunolocalisation of CD9 in control and Sdf-1-treated muscles at
ing control (ctrl) and Sdf-1-treated muscle regeneration at days 1, 3,
Figure 2 CD9 in control and injected with Sdf-1 skeletal muscles
of wild type and Pax7–/– mice. (A) Quantitative RT-PCR analysis of
mRNA encoding CD9 in wild type (wt) and Pax7–/– mice muscles at
day 7 of regeneration. (B) Immunolocalisation of CD9 in wt and Pax7–/–
mouse muscles at day 7 of regeneration. Nuclei, blue; adhesion pro-
teins, green. Bar = 30 μm. (C) Level of CD9 protein during control (C)
and Sdf-1-treated muscle regeneration of wt and Pax7–/– mice at day 7.
Error bars indicate standard deviation.
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Importantly, as we showed previously, Sdf-1 did not
change the number of rat satellite cell-derived myo-
blasts during in vitro culture, implying that it did not
impact the proliferation rate [30].
To determine whether Sdf-1 increases CD9 expression
in satellite cell-derived myoblasts or impacts on cells mi-
grating to the injured muscle, we decided to focus on
Pax7–/– mice. Previous analyses of this mouse model did
not show any abnormalities in embryonic myogenesis
[39]. However, postnatal development in Pax7–/– mice is
associated with a dramatic decrease in the population of
satellite cells, which causes the muscle growth retard-
ation [40]. As a result these mice are significantly
smaller than wild-type (wt) mice, have difficulty in mov-
ing, and usually die within 3 weeks of age. Analyses of
Pax7–/– muscles give us a unique opportunity to answer
the question about the identity of cells upregulating
CD9 within the injured muscle; that is, we were able to
test whether Sdf-1 treatment impacted on the resident
satellite cells (absent in Pax7–/– mice) or the cells that
were infiltrating injured muscle. Again, Sdf-1 treatment
increased the CD9 mRNA level only slightly (Figure 2A).
However, the level of CD9 protein was higher in Pax7–/–
and wt mice muscles as showed by immunocytochem-
istry and western blotting (Figure 2B,C). CD9 protein
exists in three forms with molecular masses between 22
and 27 kDa, and thus two CD9 bands were detected by
western blot. Summarising, we proved that Sdf-1
injected into the muscle upregulated the CD9 level also
in cells other than the satellite cells that either are
already present within or infiltrate regenerating muscle.
To answer the question of whether Sdf-1 also acts at sat-
ellite cells, we turn to the in vitro system.
The notion that Sdf-1 treatment results in upregula-
tion of CD9 in satellite cells was tested in in vitro experi-
ments in which we took advantage of primary rat
satellite cell-derived myoblasts. At day 5 of culture, sat-
ellite cell-derived myoblasts start to proliferate and then,
at day 7, fuse to form multinucleated myotubes. We did
not observe any significant differences in m-cadherin,
ADAM-12, syndecan-4, CD9, CD81, integrin beta1,
alpha3, alpha7, and alpha9 mRNA levels between control
and Sdf-1-treated cells at day 5 (nondifferentiated cells)
and day 7 of culture (fusing cells) (Figure 3A). When
Figure 3 Sdf-1 impacts on the expression of adhesion proteins (m-cadherin, ADAM-12, syndecan-4, CD9, CD81, integrin β1, integrin
α3, integrin α7, integrin α9) in differentiating rat satellite cell-derived myoblasts. (A) Level of mRNA at days 5 and 7 of control (C) and
Sdf-1-treated myoblast (Sdf-1) differentiation. (B) Immunolocalisation of adhesion proteins in control and Sdf-1-treated cells. Nuclei, blue; adhesion
proteins, green. Bar = 20 μm. (C) Level of adhesion proteins during control and Sdf-1-treated myoblast differentiation at day 7. itgb1, integrin β1;
itga3, integrin α3; itga7, integrin α7; itga9, integrin α9. *P <0.05. Error bars indicate standard deviation.
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tion and western blotting we observed a spectacular in-
crease only in the case of CD9 (Figure 3B,C).
Downregulation of Sdf-1 receptor (CXCR4) affects CD9
expression in C2C12 myoblasts
To further dissect the Sdf-1 impact on myoblast differ-
entiation we decided to manipulate the levels of its re-
ceptor; that is, CXCR4. In these experiments we used
mouse C2C12 myoblasts. The rationale behind the
choice of these cells is based on the fact that this cell
line not only serves as a standard in the studies on myo-
blast differentiation, but also is easy to manipulate and
transfect in in vitro culture. Expression of CXCR4 was
downregulated with specific siRNA. Forty-eight hours
following transfection with siRNA the level of CXCR4
mRNA decreased to 42.72 ± 2.39%, as compared with
cells transfected with control siRNA cells. In addition,
the level of CXCR7 mRNA, which was shown to be in-
volved in the Sdf-1 and interferon-inducible T-cell
chemoattractant signalling pathway [41], also slightlydecreased to 77.14 ± 8.39%. Downregulation of CXCR4
did not change significantly the levels of mRNAs encod-
ing adhesion proteins; that is, m-cadherin, ADAM-12,
syndecan-4, CD9, CD81, integrin beta1, alpha3, and
alpha7 (Figure 4A). Moreover, Sdf-1 treatment did not
impact on the levels of analysed mRNAs (Figure 4A).
However, the difference in ADAM12 mRNA level after
silencing CXCR4 expression and Sdf-1 treatment was
statistically significant (P = 0.046), but it was not statisti-
cally significant when compared with control. Next, the
expression of itga9 mRNA was very low and changed
neither after Sdf-1 treatment nor after downregulation of
CXCR4 (data not shown). The downregulation of CXCR4
level was translated to the protein level (Figure 4B). More-
over, the level of CD9 protein increased after Sdf-1 treat-
ment and decreased in response to CXCR4 downregulation
(Figure 4B). Immunolocalisation again proved that CXCR4
protein was not detectable in siRNA transfected cells
(Figure 4C). We also did not notice changes in the loca-
lisation and levels of m-cadherin, ADAM-12, syndecan-4,
CD81, integrin beta1, alpha3, alpha7, and alpha9
Figure 4 Level of CXCR4 and adhesion proteins in C2C12 myoblasts. (A) Quantitative RT-PCR analysis of mRNA encoding m-cadherin,
ADAM-12, syndecan-4, CD9, CD81, integrin β1 (itgb1), integrin α3 (itga3), integrin α7 (itga7), and integrin α9 (itga9) in control cells, treated with
Sdf-1, and transfected with CXCR4 siRNA (siRNA). (B) Western blotting analysis of CXCR4, CD9, and tubulin in control, Sdf-1-treated (Sdf-1) and
transfected with CXCR4 siRNA (siRNA) C2C12 myoblasts. (C) Immunolocalisation of CXCR4 and adhesion protein in control, treated with Sdf-1,
and transfected with CXCR4 siRNA (siRNA) C2C12 myoblasts. Nuclei, blue; adhesion proteins, green. Bar = 50 μm. CXCR, CXC chemokine receptor;
siRNA, small interfering RNA. *P <0.05. Error bars indicate standard deviation.
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induced CD9 upregulation (Figure 4C).Sdf-1 upregulates CD9 expression in bone marrow-derived
stem cells and embryonic stem cells
Our next question was whether Sdf-1 affected CD9 ex-
pression in stem cells other than satellite cells or cells
infiltrating the injured skeletal muscle. To address this
issue we decided to analyse two standard stem cell types
of different origin: multipotent adult BM-MSCs and
pluripotent ESCs. Both types of cells are extensively
studied as a source of cells that could be used in
therapy.Cells isolated from mouse bone marrow were sepa-
rated using a magnetic column and the fraction of
CXCR4-positive cells (BM-MSCsCXCR4+) – that is, only
the cells able to react to Sdf-1 – were analysed. We
showed that the level of CXCR4 protein is higher in
BM-MSCsCXCR4+ than in BM-MSCsCXCR4– or the whole
population of BM-MSCs (Figure 5A). Importantly, Sdf-1
treatment lead to the significant increase of CD9 mRNA
and protein levels in BM-MSCsCXCR4+ (Figure 5B,C).
CD9 protein exists in three forms with molecular masses
between 22 and 27 kDa, and thus two CD9 bands were
detected by western blot. Next, we tested the impact of
Sdf-1 on ESCs, control and transfected with siRNA
against CXCR4 or CXCR7. The mRNA and protein level
Figure 5 Sdf-1 impact on bone marrow mesenchymal stem
cells. (A) Western blotting analysis of CXCR4, CD9, and tubulin in
the whole population of bone marrow-derived mesenchymal stem
cells (BM-MSCs) as well as of CXCR4+ and CXCR4– BM-MSCs fractions
fractions. (B) Quantitative RT-PCR analysis of CXCR4 and CD9 mRNA in
BM-MSCs in control and Sdf-1-treated BM-MSCs. (C)Western blotting
analysis of CD9 and tubulin in control and Sdf-1-treated (Sdf-1) BM-MSCs.
(D) Migration of BM-MSCs in Sdf-1 gradient. The number of cells that
migrated from the inserts was counted. (E) Percent of hybrid myotubes formed
in co-culture of C2C12 myoblasts and control or Sdf-1 pretreated BM-MSCs. (F)
Co-culture of C2C12 myoblasts and control or Sdf-1 pretreated BM-MSCs
(green, localisation of β-galactosidase; blue, nuclei). Bar = 50 μm. CXCR,
CXC chemokine receptor. *P <0.05. Error bars indicate standard deviation.
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level of CXCR4 protein was significantly downregulated
in cells transfected with CXCR4 siRNA (Figure 6A,B).
Notably, in the response to Sdf-1, ESCs also upregulated
CD9 at the mRNA and protein levels (Figure 6A,B). Si-
lencing of CXCR4 lead to the downregulation of CD9
protein in ESCs (Figure 6B). Downregulation of CXCR4
did not change the protein level of the second Sdf-1 re-
ceptor; that is, CXCR7 (Figure 6B). We also decided to
silence expression of CXCR7 and observed that this only
slightly reduced the CD9 protein level (Figure 6B). How-
ever, silencing of CXCR7 expression was connected with
lower CXCR4 expression. We thus concluded that ob-
served lower CD9 protein expression could be the result
of CXCR4 downregulation.Stem cells treated with Sdf-1 migrate and fuse with
myoblast more effectively than control cells
Having found that Sdf-1, acting via CXCR4, upregulates
CD9 in myoblasts, cells infiltrating injured muscle, and
in such stem cells as BM-MSCs and ESCs, we decided
to assess whether this phenomenon contributes to the
improvement of skeletal muscle regeneration. We used
in vitro systems allowing assessment of the cell migra-
tion ratio and the myogenic potential of analysed cells.
First, the migration of BM-MSCs and ESCs in re-
sponse to Sdf-1 was analysed. Using the transwell migra-
tion system we showed that the number of BM-MSCs
which migrated in response to Sdf-1 increased 3.0 times
(Figure 5D). The number of ESCs that migrated in-
creased 3.25 times in the presence of Sdf-1 (Figure 6C).
Silencing of CXCR4, but not CXCR7, expression lead to
the decrease of ESC migration in response to Sdf-1
treatment (Figure 6C). Next, we analysed how Sdf-1 im-
pacts on the myogenic potential of BM-MSCs or ESCs.
To this point, we co-cultured cells pretreated with Sdf-1
with differentiating C2C12 myoblasts. Analysis of co-
culture of BM-MSCs with C2C12 cells revealed that they
were able to form 2.93 ± 2.3% of hybrid myotubes; that
is, tubules formed as a result of fusion between tested
stem cells and C2C12 myoblasts. Sdf-1 pretreatment in-
creased this number to 9.63 ± 3.5% (Figure 5E,F). Control
ESCs were able to form 0.41 ± 0.38% of hybrid myotubes.
In response to Sdf-1 pretreatment, the number of hybrid
myotubes increased to 1.13 ± 0.64% (Figure 6D,E). As
we have shown previously, ESCs very rarely fuse with
myoblasts [42]. The observed increase in the fusion
index after Sdf-1 treatment was thus an interesting re-
sult. Taken together, our results indicate that Sdf-1 up-
regulated CD9 expression in a CXCR4-dependent, but
not a CXCR7-dependent, manner, induced stem cell
migration, and increased myogenic potential of ana-
lysed stem cells.
Figure 6 Sdf-1 impact on embryonic stem cells. (A) Quantitative RT-PCR analysis of CXCR4 and CD9 mRNA in control and Sdf-1-treated
embryonic stem cells (ESCs). (B) Western blotting analysis of CXCR4, CXCR7, CD9, and tubulin in control, Sdf-1-treated (Sdf-1), and either CXCR4
(siRNA CXCR4) or CXCR7 siRNA-treated (siRNA CXCR7) ESCs. (C) Migration of control or transfected with CXCR4 or CXCR7 siRNA ESCs in response
to Sdf-1 gradient. (D) Proportion of hybrid myotubes formed in co-culture of C2C12 myoblasts and control or Sdf-1 pretreated ESCs. (E) Co-culture of
C2C12 myoblasts (red) and control or Sdf-1 pretreated ESCs (green); nuclei, blue. Bar = 50 μm. CXCR, CXC chemokine receptor. *P <0.05. Error bars
indicate standard deviation.
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Previously, we showed that Sdf-1 improved regeneration
of injured skeletal muscles by inducing stem cell mobil-
isation to injured muscle and also increasing myoblast
migration via matrix metalloproteinases MMP2 and
MMP9 [30]. However, Sdf-1 did not change the expres-
sion of myogenic regulatory factors either in vivo or
in vitro [30]. Next, many lines of evidence, including our
own studies, showed that adhesion proteins play a cru-
cial and indispensable role in skeletal muscle regener-
ation [32,33,43,44]. Thus, in the current work we tested
whether and how Sdf-1 affects expression of adhesion
proteins engaged in myoblast migration and differenti-
ation. We found that the levels of adhesion proteins in-
creased in Sdf-1-treated muscles but not in in vitro
cultured myoblasts (primary culture or cell line). This
led us to the suggestion that in vivo the increase of m-
cadherin, integrin alpha9, and ADAM12 could occur in
cells other than myoblasts engaged in the regeneration
of skeletal muscle. Nevertheless, our most important ob-
servation was that Sdf-1 induced upregulation of CD9
in vivo during wt and Pax7–/– muscle regeneration andin in vitro cultured myoblasts and such stem cells as
BMSCs and ESCs.
CD9 is a 21 to 24 kDa surface molecule that belongs
to the tetraspanins, a family of four-transmembrane do-
main proteins associated with integrin receptors, which
was described as motility-related factor engaged in mi-
gration of multiple cancer cell lines [45]. CD9 was also
shown to be associated with such integrins as α3β1,
α4β1, α5β1, α6β1, α6β4, and αIIbβ3 [45]. Interactions of
CD9 with integrins led to changes in their conformation
and activation, which results in the modulation of
integrin-dependent signalling pathways [46]. Moreover,
CD9 is directly associated with EWI-2 and CD9P-1 (also
known as EWI-F or FPRP, member of the immuno-
globulin superfamily), epidermal growth factor receptor,
and discodin domain receptor DDR1 [47-49]. Addition-
ally, the tetraspanin network modulates membrane-type
1 matrix metalloproteinase cell surface localisation and
is able to induce expression and also activate MMP2
[50,51]. By impacting at matrix metalloproteinases, CD9
may regulate not only cell migration but also tissue re-
modelling during embryonic development, angiogenesis,
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ation. Importantly, CD9 was also shown to play a role in
muscle fibre formation [52]. In 1999 Tachibana and
Hemler documented that anti-CD9 antibodies inhibited
fusion of mouse C2C12 myoblasts, without affecting
muscle-specific protein expression such as myosin heavy
chains, desmin, and actin [52]. In our previous study, we
also showed that the complex of CD9 and integrin α3β1
plays a pivotal role during satellite cell-derived myoblast
fusion and skeletal muscle regeneration [33]. Interest-
ingly, β1-deficient myoblasts that were unable to fuse
did not express CD9 [53]. Moreover, Charrin and co-
workers showed that proper muscle regeneration re-
quired CD9 and CD81 function [54]. They demonstrated
that mice lacking either CD9 or CD81, or both CD9 and
CD81, were unable to properly regenerate their skeletal
muscles. During reconstruction of CD9 and CD81-
deficient muscle, myoblasts formed giant dystrophic
myofibres. Also in vitro absence of both CD9 and CD81
led to hyperfusion of myoblasts. Myoblasts lacking either
CD9 or CD81 fused in vitro normally.
If a lack of CD9 decreases cell fusion, then its upregu-
lation should have the opposite effect. Indeed, human
rhabdomyosarcoma-derived myoblasts overexpressing
CD9 formed approximately fourfold more syncytia than
control cells [52]. In the current study we showed that
Sdf-1 seems to be a perfect trigger leading to the in-
crease in the CD9 proteins levels that promotes skeletal
muscle regeneration via induction of stem cell migration
and fusion with myoblasts. First, we noticed that Sdf-1
treatment results in upregulation of CD9 in myoblasts in
a CXCR4-dependent way. Next, using Pax7–/– mice, we
showed that Sdf-1 treatment also increased CD9 expres-
sion in cells other than satellite cells and differentiatingFigure 7 Myogenic potential of stem cells is not sufficient to apply the
in a Sdf-1 CXCR4-dependent way leads to increased ability of stem cell linesmyoblasts; that is, stem cells that infiltrate regenerating
muscles. Our in vitro studies focusing on BM-MSCs and
ESCs proved that stem cells are prone to Sdf-1/CXCR4-
dependent CD9 induction, which leads to their increased
migration and ability to fuse with myoblasts. Thus, we
suggest that preconditioning of stem cells with Sdf-1
could be an alternative approach to optimise stem cell
migration and engraftment after their injection into in-
jured skeletal muscle. Presently, the major limitation
causing the failure of clinical trials is the lack of specific
homing of cells transplanted into injured tissue [55].
Some evidence shows that Sdf-1 treatment could be a
strategy to improve the therapeutic potential of stem
cells [56]. Sdf-1 treatment of endothelial progenitor cells
improved their migration and adhesion to activated
endothelium [57]. Sdf-1-treated endothelial progenitor
cells from human umbilical cord or cord blood upregu-
lated expression of integrins (α4 and αM) and MMP2 se-
cretion [57]. Moreover, Sdf-1-treated mesangioblasts
migrated more effectively in vitro, and in vivo efficiently
engrafted mouse dystrophic muscles improving the re-
construction of muscle fibres [58]. BM-MSCs precondi-
tioning with Sdf-1 increased cell viability, proliferation,
and vascular endothelial growth factor secretion in vitro
[59]. Sdf-1 was also shown to promote homing and
proliferation of transplanted MSCs into infarcted myo-
cardium [59]. Importantly, rat hearts transplanted with
Sdf-1-pretreated MSCs showed significant neoangionesis
in the ischaemic area [59].
The therapeutic potential of MSCs such as BM-MSCs
is extensively explored. MSCs can be easily isolated from
adult tissues and cultured in vitro. Notably, these cells
exhibit no significant immunogenicity [60,61] and are
able to differentiate into various cell types, producingm in damaged skeletal muscle therapy. Induction of CD9 expression
to migrate and fuse with myoblasts. CXCR, CXC chemokine receptor.
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apoptotic, anti-inflammatory, and pro-angiogenic prop-
erties [62]. MSCs are also able to effectively follow the
myogenic programme [17]. On the other hand, ESCs
that are characterised by the potential to differentiate
in vivo into any given cell type fail to efficiently produce
some cell types in vitro. Myogenic differentiation of
ESCs does not occur spontaneously even in embryonic
bodies that mimic spatiotemporally early embryonic de-
velopment [63,64]. As was shown by Darabi and co-
workers, ESC overexpression of Pax3 or Pax7 can
effectively drive the cells into a myogenic programme
[25,26,65]. Other in vitro methods, such as culture con-
ditions [66] or various chemical treatments [67], are far
less effective. Here, we showed that upregulation of
CD9, as the result of Sdf-1 pretreatment, leads to the in-
crease in ability to migrate and fuse with myoblasts of
these two stem cell lines; that is, BM-MSCs and ESCs.
The mechanism of CD9 expression is particularly in-
teresting. It is known that CD9 mRNA exists in two
major RNA species differing only in the length of their
5′ untranslated region [68]. Efficient mRNA translation
depends, among other factors, on the supportive RNA
folding of the 5′ untranslated region; that is, the region
which contains the initiation codons. The long and short
forms of the 5′ untranslated region of CD9 mRNA have
different stability. The long 5′ untranslated region is
characterised by a complex secondary structure com-
prising a stable stem-loop. A shift from shorter to longer
5′ untranslated regions influences the CD9 protein level.
Thus, not only a reduction or increase in the absolute
quantity of CD9 mRNA can reduce or increase the level
of CD9 protein. Moreover, the mechanism of CD9 up-
regulation is concerned with some suggestions coming
from the study, which showed in human CD34+ cells
isolated from cord blood that Sdf-1 acting through
CXCR4 induced expression of CD9 via G-proteins and
kinases they activate – protein kinase C, phospholipase
C, extracellular signal-regulated kinase, and Janus kinase
2 signals [69]. Furthermore, pretreatment of human
CD34+ cells with anti-CD9 antibody significantly im-
paired their spleen and bone marrow homing [69].Conclusions
The myogenic potential of stem cells is not sufficient to
apply the cells in damaged skeletal muscle therapy. Here,
we have shown that Sdf-1, through the CXCR4 receptor,
induced expression of tetraspanin CD9 in satellite cell-
derived myoblasts, ESCs, and BM-MSCs. We showed
that upregulation of CD9 led to an increase in the ability
of stem cells lines to migrate and fuse with myoblasts
(Figure 7). Induction of CD9 could thus increase the
therapeutic potential of stem cells.Abbreviations
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